BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Acadia Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Acadia Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07284667-815@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:ACP-211: Phase 2 readout est. (NCT07284667)
DESCRIPTION:ACP-211\, phase 2\, Major Depressive Disorder.\nStudy: ACP-211 
 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant R
 esponse\nEstimated primary completion: August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/acp-211#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07284667
URL:https://assetmemo.bio/drug/acp-211#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159673-702@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Remlifanserin: Phase 2/3 readout est. (NCT06159673)
DESCRIPTION:Remlifanserin\, phase 2/3\, Alzheimer's Disease.\nStudy: ACP-20
 4 in Adults With Alzheimer's Disease Psychosis\nEstimated primary completi
 on: January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rem
 lifanserin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06159673
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029581-702@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Remlifanserin: Phase 2 readout est. (NCT07029581)
DESCRIPTION:Remlifanserin\, phase 2.\nStudy: Phase 2\, Efficacy and Safety 
 Study of ACP-204 in Lewy Body Dementia Psychosis\nEstimated primary comple
 tion: February 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 remlifanserin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07029581
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095465-702@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Remlifanserin: Phase 3 readout est. (NCT07095465)
DESCRIPTION:Remlifanserin\, phase 3.\nStudy: Phase 3\, Open Label Extension
  Study of ACP-204 in Lewy Body Dementia Psychosis\nEstimated primary compl
 etion: February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /remlifanserin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07095465
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06194799-702@assetmemo.bio
DTSTAMP:20261121T005639Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Remlifanserin: Phase 3 readout est. (NCT06194799)
DESCRIPTION:Remlifanserin\, phase 3\, Alzheimer's Disease.\nStudy: ACP-204 
 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study\nE
 stimated primary completion: April 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/remlifanserin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06194799
URL:https://assetmemo.bio/drug/remlifanserin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
